https://www.georgeinstitute.org.au/news/investment-in-diabetes-treatment-returns-almost-five-times-more-in-benefits-to-society

1.7 million Australians have diabetes and around two-thirds also have cardiovascular disease, chronic kidney disease or both. Each year in Australia hospital admissions for cardiovascular disease and end-stage kidney disease cost over $6 billion. SGLT2 inhibitors*, a class of medication developed for the treatment of diabetes, have been shown to reduce the risk of cardiovascular disease and kidney failure. A new report published by The George Institute
Read more...

;